JP2015518006A - キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 - Google Patents
キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 Download PDFInfo
- Publication number
- JP2015518006A JP2015518006A JP2015514242A JP2015514242A JP2015518006A JP 2015518006 A JP2015518006 A JP 2015518006A JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015518006 A JP2015518006 A JP 2015518006A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nasal
- solution
- antimucosal
- xylitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
Description
本出願は、米国特許法第119条(e)の下、2012年5月25日に出願の発明の名称が「XYLITOL−BASED ANTI−MUCOSAL COMPOSITIONS AND RELATED METHODS AND COMPOSITIONS」である米国特許仮出願第61/651,741に基づく利益を主張するものであり、当該出願をその全容において参照により本明細書に援用するものである。
本明細書における書面での開示は、非制限的かつ非網羅的である例示的な実施形態を記載する。図に示されるそのような例示的な実施形態のうちの特定のものに対して参照がなされる。
Claims (20)
- アレルギー状態を緩和するための経鼻溶液であって、
アレルギー状態を治療するのに有効な量の抗粘膜組成物と、
前記抗粘膜組成物によって引き起こされる鼻の乾燥を減少させるために有効な量のキシリトール及びキシロースのうちの少なくとも1つと、
を含むことを特徴とする経鼻溶液。 - 前記抗粘膜組成物が、抗ヒスタミン剤、鼻用ステロイド薬、クロモグリク酸ナトリウム、塩酸フェニレフリン、塩酸オキシメタゾリン、塩酸アゼラスチン、フロ酸モメタゾン、及び鬱血除去剤のうちの少なくとも1つを含む、請求項1に記載の経鼻溶液。
- 前記抗粘膜組成物が、天然の抗ヒスタミン剤を含む、請求項1に記載の経鼻溶液。
- 前記天然抗ヒスタミン剤が、エキナシア、カモミール及びバジルのうちの少なくとも1つを含む、請求項3に記載の経鼻溶液。
- 前記経鼻溶液が、鼻噴霧を含み、経鼻溶液を送達するように構成された鼻噴霧瓶を更に含む、請求項1に記載の経鼻溶液。
- 経鼻溶液を液滴の形で送達するように構成された鼻用ドロッパを更に含む、請求項1に記載の経鼻溶液。
- アレルギー状態を緩和するための組成物であって、
アレルギー状態の症状を減少可能な量の抗粘膜組成物であって、典型的な使用者の鼻、目、口、及び喉のうちの少なくとも1つへの乾燥作用に至らせるのに有効な乾燥薬剤を含む抗粘膜組成物と、
乾燥作用に対抗するように構成され、乾燥薬剤の乾燥作用を減少するために有効な量の多糖類、単糖類、及び/又は糖アルコールのうちの少なくとも1つと、
を含むことを特徴とするアレルギー状態を緩和するための組成物。 - 前記多糖類、単糖類、及び/又は糖アルコールのうちの少なくとも1つが、キシリトール、エリスリトール、キシロース、マニトール、マルチトール、リビトール、アラビトール、及びリボースのうちの少なくとも1つを含む、請求項7に記載の組成物。
- 前記多糖類、単糖類、及び/又は糖アルコールのうちの少なくとも1つが、キシリトール及びキシロースのうちの少なくとも1つを含む、請求項8に記載の組成物。
- 前記多糖類、単糖類、及び/又は糖アルコールのうちの少なくとも1つが、キシリトールを含む、請求項9に記載の組成物。
- 前記組成物が、経鼻溶液を含む、請求項7に記載の組成物。
- 前記経鼻溶液が、鼻噴霧を含み、前記経鼻溶液を送達するように構成された鼻噴霧瓶を更に含む、請求項11に記載の組成物。
- 前記経鼻溶液が、ゲルを含む、請求項11に記載の組成物。
- アレルギー状態を治療しながら、同時にアレルギー治療剤の乾燥作用を減少する方法であって、以下の工程、
アレルギー状態を患う被験者を同定する工程、
アレルギー状態の治療に有効な量のアレルギー治療剤を含む抗粘膜組成物と、
アレルギー治療剤の乾燥作用を減少することに有効な量でキシリトール及びキシロースのうちの少なくとも1つと、
を含む溶液を提供する工程、
前記溶液を前記被験者の鼻、目、口、及び喉のうちの少なくとも1つに送達する工程、を含むことを特徴とする方法。 - 前記溶液が、経鼻溶液を含み、前記溶液を送達する工程が、被験者の鼻に前記経鼻溶液を送達することを含む、請求項14に記載の方法。
- 前記アレルギー治療剤が、抗ヒスタミン剤、鼻用ステロイド薬、クロモグリク酸ナトリウム、塩酸フェニレフリン、塩酸オキシメタゾリン、塩酸アゼラスチン及びフロ酸モメタゾンのうちの少なくとも1つを含む、請求項14に記載の方法。
- 前記溶液が、水溶液からなる、請求項14に記載の方法。
- 前記溶液が、ゲルを含む、請求項14に記載の方法。
- 前記溶液を送達する工程が、ゲルを接着送達方法で送達することを含む、請求項18に記載の方法。
- 前記ゲルが、バイオ接着剤を含む、請求項19に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261651741P | 2012-05-25 | 2012-05-25 | |
US61/651,741 | 2012-05-25 | ||
PCT/US2013/042925 WO2013177594A2 (en) | 2012-05-25 | 2013-05-28 | Xylitol-based anti-mucosal compositions and related methods and compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015518006A true JP2015518006A (ja) | 2015-06-25 |
JP2015518006A5 JP2015518006A5 (ja) | 2017-03-23 |
Family
ID=49621806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015514242A Pending JP2015518006A (ja) | 2012-05-25 | 2013-05-28 | キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 |
Country Status (13)
Country | Link |
---|---|
US (3) | US8709508B2 (ja) |
EP (1) | EP2854781A4 (ja) |
JP (1) | JP2015518006A (ja) |
KR (1) | KR20150011807A (ja) |
CN (1) | CN104334164A (ja) |
AU (1) | AU2013266067B2 (ja) |
BR (1) | BR112014029442A2 (ja) |
CA (1) | CA2870158C (ja) |
IL (1) | IL235875A (ja) |
MX (1) | MX2014013998A (ja) |
RU (1) | RU2607892C2 (ja) |
WO (1) | WO2013177594A2 (ja) |
ZA (1) | ZA201408594B (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
AU2013266067B2 (en) | 2012-05-25 | 2016-10-06 | Xlear, Inc. | Xylitol-based anti-mucosal compositions and related methods and compositions |
JP6499077B2 (ja) | 2012-10-25 | 2019-04-10 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病と関連疾患の治療のための併用療法 |
US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
JP6545148B2 (ja) | 2013-03-13 | 2019-07-17 | フラットリー ディスカバリー ラブ,エルエルシー | ピリダジノン化合物及び嚢胞性線維症の治療のための方法 |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
JP2016534063A (ja) * | 2013-10-22 | 2016-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリン誘導体ならびに関連するイメージングおよび治療方法 |
SI3104853T1 (sl) | 2014-02-10 | 2020-03-31 | Respivant Sciences Gmbh | Zdravljenje s stabilizatorji mastocitov za sistemske motnje |
US20150224078A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
WO2018009889A1 (en) * | 2016-07-07 | 2018-01-11 | Xlear, Inc | Antibacterial nasal compositions and related methods |
CN109922800B (zh) | 2016-08-31 | 2023-06-13 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS |
AU2017423862A1 (en) | 2017-07-20 | 2020-02-06 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and ibuprofen |
AU2019299347A1 (en) | 2018-07-02 | 2021-01-21 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and alpha-lactose |
US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
WO2021216869A1 (en) | 2020-04-24 | 2021-10-28 | Joseph Scivoletto | Nasal spray composition |
WO2022140795A2 (en) * | 2020-12-23 | 2022-06-30 | Spotlight Therapeutics | Nucleic acid binding protein formulations and uses thereof |
CN116211884A (zh) * | 2023-02-16 | 2023-06-06 | 海孵(海南自贸区)医疗科技有限责任公司 | 一种鼻腔喷雾剂及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01172324A (ja) * | 1987-12-15 | 1989-07-07 | Armour Internatl Co | コレスチラミン組成物及びその製造法 |
JPH03128332A (ja) * | 1989-07-12 | 1991-05-31 | Eisai Co Ltd | α↓1―ブロッカー点眼剤 |
JP2001524108A (ja) * | 1997-04-30 | 2001-11-27 | ワーナー−ランバート・カンパニー | 局所経鼻抗炎症組成物 |
JP2002507548A (ja) * | 1998-03-24 | 2002-03-12 | ジョーンズ,アロンゾ・エイチ | 上気道状態を治療するためのキシリトール調合物 |
JP2003510275A (ja) * | 1999-09-30 | 2003-03-18 | フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物 |
US20040235807A1 (en) * | 2003-05-21 | 2004-11-25 | Weinrich Karl P. | Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea |
WO2008070264A2 (en) * | 2006-10-10 | 2008-06-12 | Case Western Reserve University | Nasal spray composition and method for treating rhinitis, sinusitis or both |
JP2008521812A (ja) * | 2004-11-24 | 2008-06-26 | メドポイント ヘルスケア インコーポレイテッド | アゼラスチンを含む組成物およびその使用方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599883B1 (en) | 1998-10-30 | 2003-07-29 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of xylitol |
EP1660056A4 (en) * | 2003-08-15 | 2008-12-17 | Arius Two Inc | BIODEGRADABLE ADHESIVE DRUG DELIVERY SYSTEM FOR MUCOUS MEMBRANES |
US20060034947A1 (en) | 2004-06-02 | 2006-02-16 | Burr James B | Erythritol compositions for nasopharynx cleansing |
US20060275223A1 (en) | 2005-06-02 | 2006-12-07 | Burr James B | Erythritol compositions for teeth and gums |
US20070286812A1 (en) * | 2006-06-09 | 2007-12-13 | Toutounghi Camille | Nasal formulation |
US20070286813A1 (en) * | 2006-06-09 | 2007-12-13 | Toutounghi Camille | Nasal formulation |
DE202010012255U1 (de) * | 2010-09-07 | 2010-11-18 | Krewel Meuselbach Gmbh | Nasenspray |
AU2013266067B2 (en) | 2012-05-25 | 2016-10-06 | Xlear, Inc. | Xylitol-based anti-mucosal compositions and related methods and compositions |
-
2013
- 2013-05-28 AU AU2013266067A patent/AU2013266067B2/en active Active
- 2013-05-28 BR BR112014029442A patent/BR112014029442A2/pt not_active Application Discontinuation
- 2013-05-28 CA CA2870158A patent/CA2870158C/en active Active
- 2013-05-28 KR KR20147031835A patent/KR20150011807A/ko not_active Application Discontinuation
- 2013-05-28 WO PCT/US2013/042925 patent/WO2013177594A2/en active Application Filing
- 2013-05-28 RU RU2014147090A patent/RU2607892C2/ru active
- 2013-05-28 US US13/903,860 patent/US8709508B2/en active Active
- 2013-05-28 EP EP13793355.2A patent/EP2854781A4/en not_active Ceased
- 2013-05-28 JP JP2015514242A patent/JP2015518006A/ja active Pending
- 2013-05-28 MX MX2014013998A patent/MX2014013998A/es not_active Application Discontinuation
- 2013-05-28 CN CN201380027507.XA patent/CN104334164A/zh active Pending
-
2014
- 2014-04-22 US US14/258,993 patent/US9011941B2/en active Active
- 2014-11-21 ZA ZA2014/08594A patent/ZA201408594B/en unknown
- 2014-11-24 IL IL235875A patent/IL235875A/en active IP Right Grant
-
2015
- 2015-01-27 US US14/606,888 patent/US20150140137A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01172324A (ja) * | 1987-12-15 | 1989-07-07 | Armour Internatl Co | コレスチラミン組成物及びその製造法 |
JPH03128332A (ja) * | 1989-07-12 | 1991-05-31 | Eisai Co Ltd | α↓1―ブロッカー点眼剤 |
JP2001524108A (ja) * | 1997-04-30 | 2001-11-27 | ワーナー−ランバート・カンパニー | 局所経鼻抗炎症組成物 |
JP2002507548A (ja) * | 1998-03-24 | 2002-03-12 | ジョーンズ,アロンゾ・エイチ | 上気道状態を治療するためのキシリトール調合物 |
JP2003510275A (ja) * | 1999-09-30 | 2003-03-18 | フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物 |
US20040235807A1 (en) * | 2003-05-21 | 2004-11-25 | Weinrich Karl P. | Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea |
JP2008521812A (ja) * | 2004-11-24 | 2008-06-26 | メドポイント ヘルスケア インコーポレイテッド | アゼラスチンを含む組成物およびその使用方法 |
WO2008070264A2 (en) * | 2006-10-10 | 2008-06-12 | Case Western Reserve University | Nasal spray composition and method for treating rhinitis, sinusitis or both |
Also Published As
Publication number | Publication date |
---|---|
IL235875A0 (en) | 2015-01-29 |
RU2607892C2 (ru) | 2017-01-11 |
RU2014147090A (ru) | 2016-07-20 |
ZA201408594B (en) | 2015-12-23 |
IL235875A (en) | 2017-10-31 |
BR112014029442A2 (pt) | 2017-06-27 |
EP2854781A4 (en) | 2016-04-13 |
AU2013266067A1 (en) | 2014-10-23 |
WO2013177594A3 (en) | 2014-01-16 |
US20150140137A1 (en) | 2015-05-21 |
US8709508B2 (en) | 2014-04-29 |
CA2870158A1 (en) | 2013-11-28 |
US20130316026A1 (en) | 2013-11-28 |
CA2870158C (en) | 2017-10-24 |
WO2013177594A2 (en) | 2013-11-28 |
MX2014013998A (es) | 2015-07-06 |
KR20150011807A (ko) | 2015-02-02 |
US9011941B2 (en) | 2015-04-21 |
CN104334164A (zh) | 2015-02-04 |
AU2013266067B2 (en) | 2016-10-06 |
US20140228304A1 (en) | 2014-08-14 |
EP2854781A2 (en) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015518006A (ja) | キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 | |
US4668513A (en) | Method for combating snoring | |
ES2493641T3 (es) | Administración nasal de soluciones acuosas de corticosteroides | |
US20110189106A1 (en) | Intranasal compositions, dosage forms and methods of treatment | |
DK2613793T3 (en) | NOSE SPRAY | |
RU2361593C3 (ru) | Комбинация азеластина и стероидов | |
US9023815B2 (en) | Method for treating rhinitis and sinusitis by rhamnolipids | |
EA008165B1 (ru) | Композиции для лечения простуды | |
US20110240012A1 (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
RU2472499C2 (ru) | Лекарственное средство, включающее комбинацию активных веществ, содержащую пантотеновую кислоту или ее производные, для лечения аллергических симптомов | |
JP2009544665A (ja) | 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤 | |
RU2701514C2 (ru) | Антивирусная фармацевтическая композиция | |
JP5584713B2 (ja) | アズレンスルホン酸ナトリウムを主剤とする点鼻薬 | |
JP2014515360A (ja) | フルチカゾンを含む鼻用医薬製剤 | |
US20160279057A1 (en) | Azelastine Formulations For Intranasal Nebulization And Irrigation | |
JP2011527344A (ja) | 静電的に帯電した多目的経鼻適用製品及び方法 | |
US20230035823A1 (en) | Antihistamine and anti-microbial nasal solutions and related methods | |
JP2002161032A (ja) | 粘膜適用組成物 | |
WO2023144614A1 (en) | Nasal compositions and methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160517 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170215 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20170215 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20170223 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171204 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180322 |